Page last updated: 2024-12-11

rhizoxin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rhizoxin: from Rhizopus chinensis; causal agent of rice seedling blight; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

rhizoxin : An macrolide antibiotic isolated from the pathogenic plant fungus Rhizopus microsporus. It also exhibits antitumour and antimitotic activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6437358
CHEMBL ID379989
CHEBI ID72590
SCHEMBL ID15955
MeSH IDM0122927

Synonyms (28)

Synonym
nsc 332598
brn 5692896
antibiotic wf-1360
crc-87/01
fr-900216
wf-1360
e-87/010
90996-54-6
rhizoxin
NSC332598 ,
nsc-332598
4,7,12,18-tetraoxatetracyclo[15.3.1.03,5.011,13]heneicos-14-ene-6,19-dione, 10-hydroxy-8-[(1s,2r,3e,5e,7e)-2-methoxy-1,3,7-trimethyl-8-(2-methyl-4-oxazolyl)-3,5,7-octatrienyl]-11,16-dimethyl-, (1s,3s,5r,8s,10s,11r,13r,16s,17r)-
hydroxy-[(1s,2r,3e,5e,7e)-2-methoxy-1,3,7-trimethyl-8-(2-methyloxazol-4-yl)octa-3,5,7-trienyl]-dimethyl-[?]dione
chebi:72590 ,
CHEMBL379989
(1s,3s,5r,8s,10s,11r,13r,14e,16r,17r)-10-hydroxy-8-[(2s,3r,4e,6e,8e)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.0(3,5).0(11,13)]henicos-14-ene-6,19-dione
unii-c1v1y784e4
c1v1y784e4 ,
SCHEMBL15955
(1s-(1r*,3r*,5s*,8r*(1r*,2s*,3e,5e,7e),10r*,11s*,13s*,14e,16s*,17s*))-10-hydroxy-8-(2-methoxy-1,3,7-trimethyl-8-(2-methyl-4-oxazolyl)-3,5,7-octatrienyl)-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo(15.3.1.03,5.011,13)heneicos-14-ene-6,19-dione
rhizoxin [mi]
4,7,12,18-tetraoxatetracyclo(15.3.1.03,5.011,13)heneicos-14-ene-6,19-dione, 10-hydroxy-8-(2-methoxy-1,3,7-trimethyl-8-(2-methyl-4-oxazolyl)-3,5,7-octatrienyl)-11,16-dimethyl-, (1s-(1r*,3r*,5s*,8r*(1r*,2s*,3e,5e,7e),10r*,11s*,13s*,14e,16s*,17s*))-
OWPCHSCAPHNHAV-QIPOKPRISA-N
DTXSID20897515
(1s,3s,5r,8s,10s,11r,13r,16r,17r,e)-10-hydroxy-8-((2s,3r,4e,6e,8e)-3-methoxy-4,8-dimethyl-9-(2-methyloxazol-4-yl)nona-4,6,8-trien-2-yl)-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.03,5.011,13]henicos-14-ene-6,19-dione
Q10861060
(1s,3s,5r,8s,10s,11r,13r,14e,16r,17r)-10-hydroxy-8-[(2s,3r,4e,6e,8e)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.03,5.011,13]henicos-14-ene-6,19-dione
AKOS040747384

Research Excerpts

Overview

Rhizoxin (NSC 332598) is a novel macrolide antitumor antibiotic that inhibits microtubule assembly and also depolymerizes preformed microtubules. Rhizoxin is a 16-membered antifungal macrocyclic lactone isolated from the pathogenic fungus Rhizopus chinensis.

ExcerptReferenceRelevance
"Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. "( Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
Bleehen, NM; Brampton, MH; Harper, P; Kaye, SB; Kerr, DJ; Rustin, GJ; Selby, P, 1995
)
2.06
"Rhizoxin is a new macrocyclic lactone isolated from the fungus Rhizopus chinensis. "( [Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer].
Genba, K; Horiguchi, T; Kiura, K; Matsumura, T; Ohnoshi, T; Segawa, Y; Shibayama, T; Tabata, M; Takigawa, N; Ueoka, H, 1993
)
2.01
"Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. "( Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.
Aamdal, S; Catimel, G; Hanauske, AR; Kaye, SB; Paridaens, R; Pavlidis, N; te Velde, A; ten Bokkel Huinink, W; Verweij, J; Wanders, J, 1996
)
2.03
"Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. "( Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
Aamdal, S; Graham, MA; Heinrich, B; McLeod, HL; Murray, LS; Pavlidis, N; Setanoians, A; ten Bokkel Huinink, WW; Verweij, J; Wagener, DJ; Wanders, J, 1996
)
1.99
"Rhizoxin is an antineoplastic drug that inhibits tubulin polymerization. "( In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance.
Abe, S; Arioka, H; Heike, Y; Nishio, K; Saijo, N, 1997
)
2.02
"Rhizoxin (NSC 332598) is a novel macrolide antitumor antibiotic that inhibits microtubule assembly and also depolymerizes preformed microtubules. "( A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors.
Aylesworth, C; Campbell, E; Izbicka, E; Kuhn, J; Rizzo, J; Rowinsky, EK; Tolcher, AW; Von Hoff, DD; Weiss, G, 2000
)
2.08
"Rhizoxin is a 16-membered antifungal macrocyclic lactone isolated from the plant pathogenic fungus Rhizopus chinensis. "( Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent.
Berger, DP; Dreef-van der Meulen, HC; Fiebig, HH; Fodstad, O; Hendriks, HR; Henrar, RE; Paull, KD; Pinedo, HM; Plowman, J; Schwartsmann, G, 1992
)
1.96
"Rhizoxin is a new macrocyclic lactone isolated from the fungus Rhizopus chinensis which displays broad-spectrum antitumor activity against murine and human tumor xenografts and has activity against a number of vincristine-resistant tumors in vitro and in vivo."( Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme.
Bissett, D; Graham, MA; Hamilton, T; Henrar, R; Kaye, SB; Kerr, DJ; Setanoians, A, 1992
)
2
"Rhizoxin is a tubulin-binding cytotoxic compound, isolated from the fungus Rhizopus chinensis, with significant antineoplastic activity in several murine and human tumor models. "( Phase I and pharmacokinetic study of rhizoxin.
Bissett, D; Cassidy, J; Chadwick, GA; Graham, MA; Henrar, R; Kaye, SB; Koier, I; Schwartsmann, G; Setanoians, A; Wilson, P, 1992
)
2
"Rhizoxin is an antitumor drug prepared from the fungus Rhizopus chinensis. "( Interaction of rhizoxin with bovine brain tubulin.
Iwasaki, S; LudueƱa, RF; Prasad, V; Roach, MC; Sullivan, AS; Takahashi, M, 1990
)
2.07

Effects

ExcerptReferenceRelevance
"Rhizoxin has shown some clinical activity in this Phase I study, and a dose of 2.0 mg/m2 is recommended for Phase II studies using this schedule."( Phase I and pharmacokinetic study of rhizoxin.
Bissett, D; Cassidy, J; Chadwick, GA; Graham, MA; Henrar, R; Kaye, SB; Koier, I; Schwartsmann, G; Setanoians, A; Wilson, P, 1992
)
1.28

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic studies were integrated with the toxicity study in female BALB/c mice at one-tenth the LD10, one-half the LD10, and the LD10 (i."( Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme.
Bissett, D; Graham, MA; Hamilton, T; Henrar, R; Kaye, SB; Kerr, DJ; Setanoians, A, 1992
)
0.56
" In all cases, considerable effort has gone into detailed pharmacokinetic studies conducted before and during the clinical phase I studies."( Pharmacokinetics and early clinical studies of selected new drugs.
Cassidy, J; Graham, MA; Jodrell, D; Kaye, SB; Workman, P, 1993
)
0.29
" In this report, we describe a mathematical model, which explains the schedule-dependent interpatient pharmacodynamic variability of rhizoxin administered on a continuous infusion schedule."( Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations.
Fleming, GF; Goh, BC; Janisch, L; Ratain, MJ; Stadler, WM; Vogelzang, NJ, 2000
)
0.74

Compound-Compound Interactions

ExcerptReferenceRelevance
"The aim of this study was to determine the antitumor activity of irofulven when administered in combination with a variety of antimitotic agents."( Enhanced antitumor activity of irofulven in combination with antimitotic agents.
Estes, LA; Kelner, MJ; McMorris, TC; Rojas, RJ; Suthipinijtham, P; Trani, NA; Velasco, TR, 2002
)
0.31

Dosage Studied

ExcerptRelevanceReference
" The presence of pharmacodynamic relationships and the low level of systemic toxicity suggest that future trials of rhizoxin with alternative dosage or treatment schedules are warranted."( Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
Aamdal, S; Graham, MA; Heinrich, B; McLeod, HL; Murray, LS; Pavlidis, N; Setanoians, A; ten Bokkel Huinink, WW; Verweij, J; Wagener, DJ; Wanders, J, 1996
)
0.76
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
antimitoticAny compound that inhibits cell division (mitosis).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
macrolide antibioticA macrocyclic lactone with a ring of twelve or more members which exhibits antibiotic activity.
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
1,3-oxazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (61)

Assay IDTitleYearJournalArticle
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID518925Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype C isolate NIH34 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID736658Inhibition of goat brain tubulin polymerization incubated for 20 mins prior to GTP addition measured for 30 mins by 90 degree light scattering-based fluorescence spectrophotometric method2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
A synthetic dolastatin 10 analogue suppresses microtubule dynamics, inhibits cell proliferation, and induces apoptotic cell death.
AID464498Inhibition of tubulin polymerization at 10 uM by fluorescence method2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID516280Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype C isolate H0058-1-818 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID518916Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH535 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID464324Cytotoxicity against human HepG2 cells after 72 hrs by luminescence assay2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID516278Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH409 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID464504Inhibition of Trypanosoma brucei brucei tubulin polymerization2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID516277Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH444 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID464511Selectivity ratio for IC50 for human BJ cells to IC50 for Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID518918Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate B4506 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID464514Selectivity for human HepG2 cells over human HMEC2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID464323Antitrypanosomal activity against Trypanosoma brucei brucei after 48 hrs by luminescence assay2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID464500Inhibition of mouse COX22010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID464518Selectivity for human Raji cells over human HMEC2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID464516Selectivity for human HEK293 cells over human HMEC2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID516316Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate RB3 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID518915Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH412 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID464515Selectivity ratio for IC50 for human BJ cells to IC50 for human HEK293 cells2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID518920Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate B5763 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID464327Cytotoxicity against human BJ cells after 72 hrs by luminescence assay2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID518919Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate B5788 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID464507Inhibition of Trypanosoma brucei brucei tubulin polymerization assessed as aberrant nuclei at 1 uM after 24 hrs by phase contrast fluorescence microscopy2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID518922Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate B3939 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID518921Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH198 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID464325Cytotoxicity against HEK293 cells after 72 hrs by luminescence assay2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID464517Selectivity ratio for IC50 for human BJ cells to IC50 for human Raji cells2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID464519Half life in stimulated gastric fluid of pH 1.02010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID464501Half life in mouse plasma by UPLC-MS analysis2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID270729Inhibition of tubulin polymerization in porcine brain at 20 uM2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Tubulin polymerization inhibitors with a fluorinated phthalimide skeleton derived from thalidomide.
AID464499Inhibition of ovine COX12010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID518923Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH184 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID518909Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH200 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID516281Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype C isolate H00581-1941 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID464508Inhibition of Trypanosoma brucei brucei tubulin polymerization assessed as aberrant nuclei at 100 nM after 24 hrs by phase contrast fluorescence microscopy2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID518917Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype C isolate NIH257 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID518924Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH189 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID516279Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH771 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID464512Selectivity for Trypanosoma brucei brucei over human HMEC2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID464513Selectivity ratio for IC50 for human BJ cells to IC50 for human HepG2 cells2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID518914Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH754 at 0.5 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID464326Cytotoxicity against human Raji cells after 72 hrs by luminescence assay2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (98)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (8.16)18.7374
1990's40 (40.82)18.2507
2000's23 (23.47)29.6817
2010's25 (25.51)24.3611
2020's2 (2.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.94 (24.57)
Research Supply Index4.74 (2.92)
Research Growth Index5.02 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (10.68%)5.53%
Reviews11 (10.68%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other81 (78.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]